415results about How to "Improve cell activity" patented technology

Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid T cell mediated responses, (2) induction of T cell exhaustion, T cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and / or other APCs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired T cell inhibition by simultaneously inhibiting the PD-1 ligands, PD-L1 and PD-L2. The immune response can be modulated by providing antagonists which bind with different affinity, by varying the dosage of agent which is administered, by intermittent dosing over a regime, and combinations thereof, that provides for dissociation of agent from the molecule to which it is bound prior to being administered again. In some cases it may be particularly desirable to stimulate the immune system, then remove the stimulation.

A composition for treating a biofilm comprises a first anchor enzyme component to degrade biofilm structures and a second anchor enzyme component having the capability to act directly upon the bacteria for a bactericidal effect.

A two component composition comprises an anchor enzyme complex to degrade biofilm structures and a second anchor enzyme component having the capability to act directly upon the bacteria for a bactericidal effect.

Increasing tolerance to butanol in yeast has been accomplished by increasing activity of the cell wall integrity pathway. Yeast with increased expression of SLT2p, a mitogen activated protein kinase of the MAPK module of the cell wall integrity pathway had increased tolerance to isobutanol. These yeast may be used for improved butanol production.

The invention discloses a cryoprotective agent of peripheral blood mononuclear cells. The cryoprotective agent is prepared from the following ingredients in parts by weight: 43-53 parts of a culture medium, 30-40 parts of auto-plasma, 12-17 parts of dimethyl sulfoxide, 5-7% of human serum albumin, and the balance being 0.17-0.23mol / L trehalose. The invention discloses a preservation method of the cryoprotective agent. The preservation method comprises the steps of collecting fresh anticoagulation blood, preparing peripheral mononuclear cells into cell suspension by using human serum albumin, adding the cryoprotective agent with the same volume as that of the cell suspension, mixing uniformly, preserving for 10-20h at below 90-below-70-below DEG C, and preserving in liquid nitrogen. According to the cryoprotective agent and the preservation method thereof, a cryopreserved cell has the high motility rate and the strong cell activity and can shorten the Cytokine Induced Killer (CIT) cell induced amplification period.

A high-strength coating for dental and orthopedic implants utilizing hydroxyapatite (HAp) nanoparticles provides for a high level of osseointegration through a range of surface pore sizes in the micro- to nanoscale. Zinc oxide (ZnO) nanoparticles may be incorporated with the HAp nanoparticles to form a composite coating material, with ZnO providing infection resistance due to its inherent antimicrobial properties. A textured surface, consisting of “islands” of roughly square coating structures measuring about 250 μm on a side, with spacing of 50-100 μm therebetween, may further promote the osseointegration and antimicrobial properties of the implant coating.

Provided is a cosmetic composition for skin protection containing Phaseolus radiatus extract of fermentation-enzyme treatment, prepared by fermenting Phaseolus radiatus with Saccharomyces cerevisiae or Lactobacillus and treating thereof with protease as an active ingredient, and a make-up method using the same. The Phaseolus radiatus extract of fermentation-enzyme treatment of the present invention contains higher isoflavone and has activities of increasing skin cell activity, alleviating skin irritation, and accelerating synthesis of skin cell protein such as collagen, so that it brings the effect of improving skin troubles caused by aging and protecting skin as well.

The invention provides a preserving fluid and a preserving method for maintaining high cell activity of a tissue sample, wherein the preserving fluid comprises the components: ion buffer solution components, carbohydrate components,, components avoiding the generation of ice crystals in and out solutions of tissue cells at a low temperature of 0-6 DEG C, components providing supplement, antioxidant and anti-apoptosis components for anabolism of the tissue cells; the preserving fluid has good biocompatibility, does not contain toxic or harmful components, and also does not contain components such as animal-derived protein, antibiotics and hormones influencing tissue gene expression. Different from traditional ultralow-temperature cryopreservation (-80 DEG C), the cryopreservation method disclosed by the invention can effectively realize low-temperature storage (0-6 DEG C) of fresh tissue samples of human beings and animals, maintains high cell activity of tissues, maintains tissue morphology, and is used for preservation and transportation of the tissue samples. Meanwhile, the nucleic acid integrity of the tissue and the stability of gene expression can be effectively maintained, the original state of the tissue is maintained, and the method can be used for gene detection, scientific research and other related experiments.

The invention relates to amethod for efficientlyobtaining mesenchymal stem cells from umbilical cord tissues and aims at solving the problems of the long obtaining time and low efficiency of an existing method. The method comprises the steps that primary isolation of umbilical cord mesenchymal stem cells is performed: cleaned and cut umbilical cord tissue blocks are predigested by using trypsin and then digestive juice is removed, repeated flushing is performed with DPBS, then digestion is performed on a water bath shaker of 37 DEG C by using collagenase I digestive juice, a complete culture solution is added to the filtrate filtered by a cell strainer to terminate digestive centrifugal separation so as to obtain primary mesenchymal stem cell; residual tissue blocks are collected after filtration, and re-digestion is performed to obtain primary mesenchymal stem cells; the mesenchymal stem cells are inoculated in the complete culture solution, and standing and culture is performed in 5% CO2 culture box at the temperature of 37 DEG C; a culture solution is replaced for one time at intervals of several days; culture multiplication is performed: when the primary cells grow to be 80% and converge, TrypLE heavy suspension cells are subjected to culture multiplication in a serum-free culture solution. The method has the advantages of efficiently obtaining mesenchymal stem cells, and the obtained mesenchymal stem cells have highcell activity and differentiation potential.